肝癌合并门静脉癌栓的外科治疗进展
Progress in Surgical Treatment of Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus
DOI: 10.12677/ACM.2022.12111521, PDF,   
作者: 李 玮*：青海大学研究生院，青海 西宁；王海久#：青海大学附属医院肝胆胰外科，青海 西宁
关键词: 肝细胞癌；门静脉癌栓；外科；治疗进展； Portal Vein Tumor Thrombus； Surgery； Progress in Treatment
摘要: 肝细胞癌(hepatocellular carcinoma, HCC)是恶性肿瘤相关死亡的主要原因之一。门静脉癌栓(portal vein tumor thrombus, PVTT)是与HCC相关的最常见的大血管侵犯形式，发生率为10%~60%。如果仅给予支持性治疗，合并PVTT的HCC患者的中位生存期约为2.7个月。过去，索拉非尼是指南唯一推荐的治疗方法，但其疗效有限。这篇叙述性综述旨在总结目前HCC合并PVTT的治疗方案及研究进展。
Abstract: Hepatocellular carcinoma is one of the leading causes of cancer-related death. Portal vein tumor thrombus is the most common form of macrovascular invasion associated with hepatocellular car-cinoma, with an incidence of 10%~60%. The median survival of HCC patients with PVTT is approxi-mately 2.7 months if supportive care alone is given. In the past, sorafenib was the only treatment recommended by guidelines, with limited efficacy. This narrative review aims to summarize the current treatment options and research progress of hepatocellular carcinoma with portal vein tu-mor thrombus formation.
文章引用：李玮, 王海久. 肝癌合并门静脉癌栓的外科治疗进展[J]. 临床医学进展, 2022, 12(11): 10566-10572. https://doi.org/10.12677/ACM.2022.12111521

参考文献

[1] Gordan, J.D., Kennedy, E.B., Abou-Alfa, G.K., et al. (2020) Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 38, 4317-4345. [Google Scholar] [CrossRef] 
[2] Yang, J.D., Hainaut, P., Gores, G.J., et al. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. [Google Scholar] [CrossRef] [PubMed]
[3] Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 7.[CrossRef] [PubMed]
[4] Yin, J., Bo, W.T., Sun, J., et al. (2017) New Evidence and Per-spectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology, 5, 169-176.
[5] Yang, Z., Zou, R., Zheng, Y., et al. (2019) Lipiodol Deposition in Portal Vein Tumour Thrombus Predicts Treatment Outcome in HCC Patients after Transarterial Chemoembolisation. European Radiology, 29, 5752-5762. [Google Scholar] [CrossRef] [PubMed]
[6] Kuo, Y.-H., Wu, I.P, Wang, J.-H., et al. (2017) The Outcome of Sorafenib Monotherapy on Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Investigational New Drugs, 36, 307-314. [Google Scholar] [CrossRef] [PubMed]
[7] Su, G.L., Altayar, O., O’Shea, R., et al. (2022) AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology, 162, 920-934. [Google Scholar] [CrossRef] [PubMed]
[8] Bruix, J., Chan, S.L., Galle, P.R., Rimassa, L. and Sangro, B. (2021) Systemic Treatment of Hepatocellular Carcinoma: An EASL Position Paper. Journal of Hepatology, 75, 960-974. [Google Scholar] [CrossRef] [PubMed]
[9] Kudo, M., Kawamura, Y., Hasegawa, K., et al. (2021) Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 10, 181-223. [Google Scholar] [CrossRef] [PubMed]
[10] Cerrito, L., Annicchiarico, B.E., Iezzi, R., et al. (2019) Treatment of Hepa-tocellular Carcinoma in Patients with Portal Vein Tumor Thrombosis: Beyond the Known Frontiers. World Journal of Gastroenterology, 25, 4360-4382. [Google Scholar] [CrossRef] [PubMed]
[11] 中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
[12] Wu, B., Zhang, Y., Tan, H. and Shi, H. (2019) Value of 18F-FDG PET/CT in the Diagnosis of Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma. Abdominal Radiology, 44, 2430-2435. [Google Scholar] [CrossRef] [PubMed]
[13] Kudo, M., Izumi, N., Kubo, S., et al. (2020) Report of the 20th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan. Hepatology Research, 50, 15-46. [Google Scholar] [CrossRef] [PubMed]
[14] Shi, J., Lai, E.C., Li, N., et al. (2011) A New Classification for Hepatocel-lular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepato-Biliary-Pancreatic Sciences, 18, 74-80. [Google Scholar] [CrossRef] [PubMed]
[15] West, H.J. and Jin, J.O. (2015) Transarterial Chemoembolization. JAMA Oncology, 1, 1178. [Google Scholar] [CrossRef] [PubMed]
[16] Niu, Z.J., Ma, Y.L., Kang, P., et al. (2012) Transarterial Che-moembolization Compared with Conservative Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Using a New Classification. Medical Oncology, 29, 2992-2997. [Google Scholar] [CrossRef] [PubMed]
[17] Xiang, X., Lau, W.Y., Wu, Z.Y., et al. (2019) Transarterial Che-moembolization versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombusa Multicenter Study. European Journal of Surgical Oncology, 45, 1460-1467. [Google Scholar] [CrossRef] [PubMed]
[18] Ni, J.Y., Sun, H.L., Luo, J.H., et al. (2019) Transarterial Che-moembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy. Cancer Management and Research, 11, 9939-9950. [Google Scholar] [CrossRef] 
[19] Langendijk, J.A., Boersma, L.J., Rasch, C.R.N., et al. (2018) Clini-cal Trial Strategies to Compare Protons with Photons. Seminars in Radiation Oncology, 28, 79-87. [Google Scholar] [CrossRef] [PubMed]
[20] Huo, Y.R. and Eslick, G.D. (2015) Transcatheter Arterial Chemoembolization plus Radiotherapy Compared with Chemoembolization Alone for Hepatocellular Carcinoma: A Sys-tematic Review and Meta-analysis. JAMA Oncology, 1, 756-765. [Google Scholar] [CrossRef] [PubMed]
[21] Hu, H.T., Luo, J.P., Cao, G.S., et al. (2021) Hepatocellular Car-cinoma with Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. 125Iodine Implantation. Frontiers in Oncology, 11, Article 806907. [Google Scholar] [CrossRef] [PubMed]
[22] Sangro, B. and Salem, R. (2014) Transarterial Chemoembolization and Radioembolization. Seminars in Liver Disease, 34, 435-443. [Google Scholar] [CrossRef] [PubMed]
[23] Mikell, J.K., Dewaraja, Y.K. and Owen, D. (2020) Transarterial Ra-dioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semi-nars in Radiation Oncology, 30, 68-76. [Google Scholar] [CrossRef] [PubMed]
[24] Kooby, D.A., Egnatashvili, V., Srinivasan, S., et al. (2010) Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unre-sectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 21, 224-230. [Google Scholar] [CrossRef] [PubMed]
[25] Salem, R., Gabr, A., Riaz, A., et al. (2018) Institutional Decision to Adopt Y90 as Primary Treatment for Hepatocellular Carcinoma Informed by a 1,000-Patient 15-Year Experience. Hepa-tology, 68, 1429-1440. [Google Scholar] [CrossRef] [PubMed]
[26] Mazzaferro, V., Sposito, C., Bhoori, S., et al. (2013) Yttrium-90 Radioem-bolization for Intermediate-Advanced Hepatocellular Carcinoma: A Phase 2 Study. Hepatology, 57, 1826-1837. [Google Scholar] [CrossRef] [PubMed]
[27] Ahn, J.C., Lauzon, M., Luu, M., et al. (2021) Transarterial Radioemboliza-tion versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the US National Cancer Database. Journal of Nuclear Medicine, 62, 1692-1701. [Google Scholar] [CrossRef] [PubMed]
[28] Lu, Z.H., Shen, F., Yan, Z.L., et al. (2009) Treatment of Portal Vein Tumor Thrombus of Hepatocellular Carcinoma with Percutaneous Laser Ablation. Journal of Cancer Research and Clinical Oncology, 135, 783-789. [Google Scholar] [CrossRef] [PubMed]
[29] Tarantino, L., Busto, G., Nasto, A., et al. (2017) Percutaneous Electrochemotherapy in the Treatment of Portal Vein Tumor Thrombosis at Hepatic Hilum in Patients with Hepatocellular Carcinoma in Cirrhosis: A Feasibility Study. World Journal of Gastroenterology, 23, 906-918. [Google Scholar] [CrossRef] [PubMed]
[30] Hong, T.S., Wo, J.Y., Yeap, B.Y., et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepato-cellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 34, 460-468. [Google Scholar] [CrossRef] 
[31] Tse, R.V., Hawkins, M., Lockwood, G., et al. (2008) Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarci-noma. Journal of Clinical Oncology, 26, 657-664. [Google Scholar] [CrossRef] 
[32] Zhang, S., He, L., Bo, C., et al. (2021) Comparison of Stereotactic Body Radiation Therapy versus Fractionated Radiation Therapy for Primary Liver Cancer with Portal Vein Tumor Thrombus. Radiation Oncology, 16, Article No. 149. [Google Scholar] [CrossRef] [PubMed]
[33] Kondo, M., Morimoto, M., Kobayashi, S., et al. (2019) Ran-domized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial. BMC Cancer, 19, Article No. 954. [Google Scholar] [CrossRef] [PubMed]
[34] Kudo, M., Ueshima, K., Yokosuka, O., et al. (2018) Sorafenib plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy versus Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial. The Lancet Gastroen-terology & Hepatology, 3, 424-432. [Google Scholar] [CrossRef] 
[35] He, M., Li, Q., Zou, R., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. [Google Scholar] [CrossRef] [PubMed]
[36] Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. [Google Scholar] [CrossRef] [PubMed]
[37] Lyu, N., Wang, X., et al. (2022) Arterial Chemotherapy of Oxali-platin plus Fluorouracil versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Random-ized, Phase III Trial (FOHAIC-1). Journal of Clinical Oncology, 40, 468-480. [Google Scholar] [CrossRef] 
[38] Kokudo, T., Hasegawa, K., Matsuyama, Y., et al. (2016) Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Hepatology, 65, 938-943. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, K., Guo, W.X., Chen, M.S., et al. (2016) Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine, 95, e3015. [Google Scholar] [CrossRef] 
[40] Liu, S., Guo, L., Li, H., et al. (2018) Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 25, 2098-2104. [Google Scholar] [CrossRef] [PubMed]

为你推荐